by Josh Mitteldorf, PhD, The Pulse: In September, the U.S. Food and Drug Administration (FDA) — over the objections of the agency’s own advisors — authorized Pfizer’s COVID-19 bivalent booster on an emergency basis, without any testing or demonstration that the products had any benefit in human beings. The only “emergency” was that collapsing demand for Pfizer’s […]
Source